Scientific Organizers:

**David A. Hafler**, Yale University School of Medicine, USA

**Vijay K. Kuchroo**, Brigham and Women’s Hospital, Harvard Medical School, USA

**Jane L. Grogan**, Genentech, Inc., USA

While the importance of innate and adaptive immunity has been clear in the pathogenesis of human autoimmune disease resulting in a multitude of immune-based therapeutic approaches, the realization is now apparent that understanding immune evasion by cancer is central in developing curative treatments. This meeting will explore and contrast the underlying immune mechanisms resulting in autoimmunity and tumor evasion. The meeting is innovative in bringing together basic immunologists investigating mechanisms of tolerance with scientists exploring immune mechanisms of autoimmunity and cancer in both patients and experimental models. Thus, this Keystone Symposia meeting will cover the pathways in immunity and tolerance that lead to loss of immunological control, dysregulated immune responses and chronic inflammatory disease or tumor evasion. Presentations will include consideration of preclinical and clinical aspects of a diverse number of autoimmune and inflammatory diseases and cancer. Conference participants engaged in preclinical, translational and clinical research will hopefully engage in continuing conversations and collaborations which, over the long-term, will provide greater insights into the human immune response and allow us to reassess and further explore pathways that are driving autoimmune disease yet in opposition, lead to tumor evasion. Understanding checkpoints in autoimmunity and immune cell tolerance is important for delivering therapies to patients with autoimmune disease and cancer, and this meeting will provide a platform for the cross-pollination of clinical experience and experimental research. Attendees will have learned about the impact of targeted immune-based therapeutics on clinical outcome and, consequently, be able to widen their research scope accordingly.

**Session Topics:**

- Tissue Micro-Immune Environments in Tumors and Autoimmune Tissue Inflammation
- Basic Mechanisms of T Cell Tolerance
- Metabolic Regulation of T Cell Function in Cancer and Autoimmunity
- Effector T Cell Dysfunction: Surface Receptors in Autoimmunity vs. Cancer
- Innate Regulation of Autoimmunity and Cancer
- B Cell Regulation of Autoimmunity
- 10 Years of Discovery of Th17 Cell. From Bench to Bedside
- Systems Biology Approaches to Understanding Tolerance in Cancer and Autoimmunity

**Scholarship Application & Discounted Abstract Deadline: November 29, 2016**

**Abstract Deadline: January 10, 2017**

**Discounted Registration Deadline: January 25, 2017**

Note: Scholarships are available for graduate students and postdoctoral fellows and are awarded based on the abstract submitted.


Meeting Hashtag: #KSimmreg

www.keystonesymposia.org/17D1

Immune Regulation in Autoimmunity and Cancer

March 26–30, 2017 | Whistler Conference Centre | Whistler, British Columbia | Canada
SUNDAY, MARCH 26
Arrival and Registration

MONDAY, MARCH 27
Welcome and Keynote Address
*David A. Hafler, Yale University School of Medicine, USA
James P. Allison, University of Texas MD Anderson Cancer Center, USA
Cancer Immunotherapy

Tissue Micro-Immune Environments in Tumors and Autoimmune Tissue Inflammation
Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
*From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy
Jennifer L. Gommerman, University of Toronto, Canada
Compartmentalization of B Cells During CNS Inflammation
*Jane L. Grogan, Genentech, Inc., USA
Immunoregulatory Roles of TIGIT and PVR-nectin Family in Tumors
Abigail E. Overacre, University of Pittsburgh, USA
Short Talk: Interferon-gamma drives Treg Functional Instability thereby Promoting Anti-Tumor Immunity

Workshop 1: Effector T Cells
*Thomas Korn, Technical University Munich, Germany
*Jane L. Grogan, Genentech, Inc., USA
June-Yong Lee, New York University School of Medicine, USA
Systemic and Local Functions of Serum Amyloid A (SAA) in Th17 Cell Pathogenicity
Jinju Lee, Kyoto University Graduate School of Medicine, Japan
Regulation of Th17 Expansion by PGE2-EP2/EP4 Signaling and its Clinical Implication
Pradip Nair, Biocorn Research Limited, India
T Cell Activation and Differentiation to Th17 Cells is Modulated by a CD6 Domain 1 Antibody Itolizumab
Patricia Castillo, University of Pittsburgh, USA
Disrupted Enteric Th17 Signaling Exacerbates Autoimmune Inflammation
Michael Waterfield, University of California, San Francisco, USA
Characterization of a Novel Epigenetic Regulator Required for Th17 Differentiation
Mark S. Sundrud, The Scripps Research Institute, USA
The Xenobiotic Transporter Mdr1 Permits T Cell Adaptation to Mucosa-Associated Bile Acids in the Ileum
Geoffrey Alexander Smith, University of California, San Francisco, USA
IL-2RB Receptor Levels Tune T-Cell IL-2 Responses by Altering Signaling Dynamics in Different T Cell Subsets
Peter A. Morawski, NIAID, National Institutes of Health, USA
Brain Infiltrating CD8+ T Cells in Lupus-Prone Mice

Basic Mechanisms of T Cell Tolerance
*Jeffrey A. Bluestone, University of California, San Francisco, USA
Treg Biology and Treatment in Autoimmune Diseases and Cancer
David A. Hafler, Yale University School of Medicine, USA
IFNgamma Identifies Dysfunctional Regulatory T Cells in Autoimmunity and Cancer
Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Regulatory T Cells in Cancer

Poster Session 1

TUESDAY, MARCH 28

Workshop 2: Tregs in Autoimmunity and Cancer
*Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
*Ana Carrizosa Anderson, Harvard Medical School, USA
Liliana Elisa Lucca, Yale University, USA
High CD5 Expression is a Marker of Functional Regulatory T Cells in Autoimmunity
Maran L. Sprouse, University of Pittsburgh, USA
Immunomodulation Requirements for Treg Immunotherapy for Autoimmune Diabetes
Catherine Konopacki, Memorial Sloan Kettering Cancer Center, USA
Foxp1 Is a Foxp3 Binding Partner that Contributes to Regulatory T Cell Stability and Function
Allison L. Bayer, University of Miami School of Medicine, USA
Immunomodulation Requirements for Treg Immunotherapy for Autoimmunity and Cancer
Danbee Ha, Osaka University, Japan
ADCC-Mediated in vitro Depletion of Human Treg Cells by Anti-CTLA-4 mAb Enhances CD8+ T Cell Responses against Self/Tumor Antigens
David Bauche, University of California, San Francisco, USA
IFN-gamma Drives Treg Functional Instability thereby Promoting Anti-Tumor Immunity
Merck, USA
Pfizer Inc. and Roche. This activity was supported by an educational grant from Celgene Corporation.

For the most up-to-date details, visit www.keystonesymposia.org/17D1.
Dana Catherine Gilmore, University of Chicago, USA
Identification of Natural Peptide Epitopes Recognized by Regulatory T Cells

Effector T Cell Dysfunction: Surface Receptors in Autoimmunity vs. Cancer
*Arlene H. Sharpe*, Harvard Medical School, USA
Role of Coinhibitory Receptors in Controlling Effector T Cells

**E. John Wherry**, University of Pennsylvania, USA
Molecular Basis of T Cell Exhaustion: Insights for Immunotherapy

Ana Carrizosa Anderson, Harvard Medical School, USA
T Cell Dysfunction: From Co-Inhibitory Receptors to Molecular Programs

Christopher E. Rudd, University of Montreal, Canada
Short Talk: A Next Generation Approach using Small Molecules to Inhibit PD-1 Transcription Is as Effective as Anti-PD-1/PL1 Biologics in Immunotherapy

**Poster Session 2**

**WEDNESDAY, MARCH 29**

Innate Regulation of Autoimmunity and Cancer
*Nina Bhardwaj*, Icahn School of Medicine at Mount Sinai, USA
Role of Dendritic Cells and NK Cells in Mediating Anti-Tumor Responses

**Federica Sallusto**, University of Italian Switzerland, Switzerland
Autoreactive T Cells in Narcoleptic Patients

*Carla V. Rothlin*, Yale University, USA
Innate Immune Checkpoints in Anti-Tumor Immunity

**Mark J. Smyth**, QIMR Berghofer Medical Research Institute, Australia
Barriers to NK Cell Control of Cancer

**Keiji Hirota**, Institute for Frontier Life and Medical Sciences, Kyoto University, Japan
Short Talk: An Inflammatory Cellular Network of Autoimmune Th17 Cells, GM-CSF-Producing ILCs and Synoviocytes in the Development of Autoimmune Arthritis

Workshop 3: T Cell Tolerance, Exhaustion and Dysfunction in Autoimmunity and Cancer
*Kenneth Smith*, University of Cambridge, UK

**Rachel S. Friedman**, National Jewish Health and University of Colorado, Denver, USA
MerTK Mediates T Cell Tolerance in the Pancreatic Islets during Type 1 Diabetes

**Yemsratch A. Akalu**, Yale University School of Medicine, USA
An eMERging Target in Cancer Immunotherapy

**Rachael Bashford-Rogers**, University of Cambridge, UK
Using High-Throughput Sequencing to Reveal Insights into the Relationship between B-Cell Repertoire, Phenotype and Function in Health, Cancer and Autoimmune Disease

**David M. Sansom**, University College London Medical School, UK
CTLA-4 Mutations from Patients with Immune Dysregulation Syndromes Inform our Understanding of CTLA-4 Function

**Jennifer Lori Blanchfield**, Emory University, USA
MOG-Specific Tolerance Mechanisms Limit Autoimmune Demyelinating Disease following Bacterial Delivery of MOG Epitope

**John R. Sedy**, Sanford Burnham Prebys Medical Discovery Institute, USA
Cancer Mutations Targeting TNFRSF14 alter Microenvironment Checkpoint Interactions to Limit Tumor Clearance by Cytotoxic Cells

**Greg M. Delgoffe**, University of Pittsburgh, USA
Defects in Mitochondrial Biogenesis and Oxidative Function Underlie Tumor-Infiltrating T Dysfunction

**B Cell Regulation of Autoimmunity**
*Antonio Lanzavecchia*, Institute for Research in Biomedicine, Switzerland
Mechanisms of Antibody Diversification

**Kenneth Smith**, University of Cambridge, UK
Predicting and Explaining the Future: A New Biology of Clinical Outcome in Autoimmunity?

**Alicia Gonzalez-Martin**, The Scripps Research Institute, USA
Short Talk: MicroRNA Control of B Cell Tolerance and Autoimmunity

**Bonnie Huang**, NHGRI, National Institutes of Health, USA
Short Talk: Dissecting T Follicular Helper Cell Development in vivo using CRISPR

**Poster Session 3**

**THURSDAY, MARCH 30**

Ten Years of Discovery of Th17 Cells: From Bench to Bedside
*Vijay K. Kuchroo*, Brigham and Women’s Hospital, Harvard Medical School, USA
Transcriptional Networks in Development of Th17 Cells

**Dan R. Littman**, HHMI/New York University School of Medicine, USA
Th17 Cells in the Gut Homoeostasis

**Thomas Korn**, Technical University Munich, Germany
Trans-presentation of IL-6 by Dendritic Cells - A Novel Mode of IL-6 Signaling – Is Required for the Priming of Pathogenic TH17 Cells in vivo

**Daniel J. Cua**, Merck Research Laboratories, USA
The IL-23-Th17 Immune Axis: From Mechanisms to Therapeutic Testing

**Dhavalkumar D. Patel**, Inflazome, Switzerland
Therapeutic Targeting of Th17 Cells in Autoimmune Diseases

**Systems Biology Approaches to Understanding Tolerance in Cancer and Autoimmunity**
*Frank Oliver Nestle*, Sanofi, USA
Deciphering the Rules of Engagement of Tissue Immunity

**Alex Marson**, University of California, San Francisco, USA
Decoding T Cell Circuity

**Meromit Singer**, Broad Institute, USA
Short Talk: Identification and Validation of a Gene Module Specific for T Cell Dysfunction in Tumor via Population and Single-Cell Transcriptomics

**Meeting Wrap-Up: Outcomes and Future Directions (Organizers)**

* Session Chair † Invited but not yet accepted  Program current as of September 6, 2017. Program subject to change. Meal formats are based on meeting venue.
For the most up-to-date details, visit www.keystonesymposia.org/17D1.
FRIDAY, MARCH 31

Departure